RUNX1 and hematologic disorder: This kinase stimulates protein synthesis [33]. Another agent, clustered regulatory interspaced short palindromic repeats-associated genes (CRISPR-Cas) can be used as a genomic targeted treatment as this agent can edit the RUNX1 gene by cutting pieces of DNA where RUNX1 mutations are, followed by stimulating natural DNA repair [6]. Finally, hypoxia-inducible factor 1α (HIF-1α) in­hibitor can potentially treat various hematological malignancies as a modulator of cell metabolism.